1,4-thiazines Patents (Class 514/227.5)
  • Publication number: 20040235833
    Abstract: The invention relates to indole derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The indole derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Application
    Filed: March 12, 2004
    Publication date: November 25, 2004
    Applicant: Pfizer Inc
    Inventors: Alan Daniel Brown, Justin Stephen Bryans, Mark Edward Bunnage, Paul Alan Glossop, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite, Simon John Mantell
  • Publication number: 20040235831
    Abstract: The invention relates to a composition for caring for or making up the hair or the eyelashes, which is intended to limit their loss and/or to increase their density, and containing a pyrazole compound of formula (I), or a salt thereof: 1
    Type: Application
    Filed: November 20, 2003
    Publication date: November 25, 2004
    Applicant: SOCIETE L'OREAL, S.A.
    Inventors: Roger Rozot, Christophe Boulle
  • Publication number: 20040235836
    Abstract: The present application describes modulators of MCP-1 of formula (I): 1
    Type: Application
    Filed: April 29, 2004
    Publication date: November 25, 2004
    Inventor: Robert J. Cherney
  • Publication number: 20040235832
    Abstract: One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.
    Type: Application
    Filed: January 28, 2004
    Publication date: November 25, 2004
    Inventors: Xinhe Wu, Brian M. Aquila, Liming Shao, Heike Radeke, Gregory D. Cuny, James R. Hauske, Roger L. Xie
  • Publication number: 20040235830
    Abstract: The invention relates to substituted cyclohexane derivates of formula (I), a method for the production thereof and the use thereof in medicaments, particularly for preventing and/or treating cardiovascular diseases, diseases of the urogenital tract and cerebrovascular diseases.
    Type: Application
    Filed: April 22, 2004
    Publication date: November 25, 2004
    Inventors: Susanne Rohrig, Andreas Stolle, Julio C. Castro-Palomino, Helmut Haning, Gabriele Handke-Erguden, Noemi Daviu-Folguera, Holger Paulsen, Josef Pernerstorfer, Stephan-Nicholas Wirtz, Henning Steinhagen, Wolfgang Thielemann, Erwin Bischoff, Ulrich Ebbinghaus-Kintscher, Peter Ellinghaus, Joachim Hutter, Thomas Krahn, Frank Wunder, Klemens Lustig, Joachim Schuhmacher, Frank Sussmeier
  • Publication number: 20040229895
    Abstract: The invention relates to Tetracyclic Benzamide Derivatives; compositions comprising a Tetracyclic Benzamide Derivative; and methods for treating or preventing an inflammatory disease, a reperfusion disease, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, or cancer, comprising administering to a subject in need thereof an effective amount of a Tetracyclic Benzamide Derivative.
    Type: Application
    Filed: February 26, 2004
    Publication date: November 18, 2004
    Applicant: Inotek Pharmaceuticals Corporation
    Inventors: Prakash Jagtap, William Williams, Alexander Nivorozhkin, Csaba Szabo
  • Publication number: 20040229869
    Abstract: Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.
    Type: Application
    Filed: March 26, 2004
    Publication date: November 18, 2004
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Sangita, Atul Kumar, Man Mohan Singh, Girish Kumar Jain, Puvvada Sri Ramanchandra Murthy, Suprabhat Ray
  • Publication number: 20040229868
    Abstract: The compounds of the present invention are of formula I: 1
    Type: Application
    Filed: August 29, 2003
    Publication date: November 18, 2004
    Applicant: MEMORY PHARMACEUTICALS CORP.
    Inventors: Brian Herbert, Wenge Xie, Truc Minh Nguyen, Allen T. Hopper, Ashok Tehim
  • Publication number: 20040224941
    Abstract: Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.).
    Type: Application
    Filed: November 10, 2003
    Publication date: November 11, 2004
    Inventors: Takuya Seko, Masahiko Terakado, Hiroshi Kohno, Shinya Takahashi
  • Publication number: 20040224945
    Abstract: The present invention relates to novel substituted pyrazole derivatives of the general formula (I) 1
    Type: Application
    Filed: May 28, 2004
    Publication date: November 11, 2004
    Applicant: Bayer HealthCare AG
    Inventors: Alexander Straub, Achim Feurer, Cristina Alonso-Alija, Johannes-Peter Stasch, Elisabeth Perzborn, Joachim Hutter, Klaus Dembowsky, Elke Stahl
  • Publication number: 20040224944
    Abstract: This invention describes novel pyrazole compounds of formula IV: 1
    Type: Application
    Filed: July 22, 2003
    Publication date: November 11, 2004
    Inventors: David Bebbington, Hayley Binch, Ronald Knegtel, Julian Golec, Sanjay Patel, Jean-Damien Charrier, David Kay, Robert Davies, Pan Li, Marion Wannamaker, Cornelia Forster, Albert Pierce
  • Publication number: 20040220183
    Abstract: The invention relates to new hydroxyindoles of the Formula, 1
    Type: Application
    Filed: May 27, 2004
    Publication date: November 4, 2004
    Inventors: Norbert Hofgen, Ute Egerland, Hildegard Poppe, Degenhard Marx, Stefan Szelenyi, Thomas Kronbach, Emmanuel Polymeropoulos, Sabine Heer
  • Publication number: 20040220170
    Abstract: Compounds of the present invention modulate PN3 in mammals and are useful in treating pain in mammals.
    Type: Application
    Filed: May 1, 2003
    Publication date: November 4, 2004
    Inventors: Robert N. Atkinson, Irene Drizin, Robert J. Gregg, Michael F. Gross, Michael E. Kort, Lei Shi
  • Publication number: 20040220182
    Abstract: Novel compounds of the formula I 1
    Type: Application
    Filed: April 28, 2004
    Publication date: November 4, 2004
    Inventors: Teresa Mujica-Fernaud, Herwig Buchholz, Wilfried Rautenberg, Christian Sirrenberg
  • Patent number: 6812227
    Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: November 2, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy I. Levin, James M. Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Publication number: 20040214820
    Abstract: The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.
    Type: Application
    Filed: December 31, 2003
    Publication date: October 28, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GmbH
    Inventors: Heinz-Werner Kleemann, Jean-Christophe Carry, Pascal Desmazeau, Serge Mignani, Jean Bouoquerel, Arielle Genevois-Borella, Baptiste Ronan
  • Publication number: 20040214817
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: November 17, 2003
    Publication date: October 28, 2004
    Inventors: Albert C. Pierce, Michael Amost, Robert J. Davies, Cornelia J. Forster, Vincent Galullo, Ronald Grey, Mark Ledeboer, Shi-Kai Tian, Jinwang Xu, Hayley Binch, Brian Ledford, David Messersmith, Suganthi Nanthakumar, Andrew Jayaraj, Greg Henkel, Francesco G. Salituro, Jian Wang
  • Publication number: 20040209846
    Abstract: One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.
    Type: Application
    Filed: January 7, 2004
    Publication date: October 21, 2004
    Inventors: Gregory D. Cuny, Liming Shao, James R. Hauske, Michele L.R. Heffernan, Brian M. Aquila, Xinhe Wu, Fengjiang Wang, Thomas D. Bannister
  • Publication number: 20040209858
    Abstract: The present invention relates to the use of compounds of formula (I) 1
    Type: Application
    Filed: October 22, 2003
    Publication date: October 21, 2004
    Inventors: Youssef L. Bennani, Steve A. Chamberlin, Sanjay R. Chemburkar, Jinhua Chen, Michael J. Dart, Ashok K. Gupta, Lei Wang
  • Publication number: 20040209872
    Abstract: Certain piperazine substituted compounds are described which are useful in altering calcium channel activity.
    Type: Application
    Filed: December 23, 2003
    Publication date: October 21, 2004
    Inventors: Terrance P. Snutch, Gerald W. Zamponi, Hassan Pajouhesh, Hossein Pajouhesh, Francesco Belardetti
  • Publication number: 20040209867
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: April 20, 2004
    Publication date: October 21, 2004
    Applicant: Wyeth
    Inventors: Derek Cecil Cole, Joseph Raymond Stock, William Joseph Lennox, Ping Zhou
  • Publication number: 20040209873
    Abstract: Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals
    Type: Application
    Filed: February 27, 2004
    Publication date: October 21, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Christian Stapper, Heiner Glombik, Eugen Falk, Jochen Goerlitzer, Dirk Gretzke, Stefanie Keil, Hans-Ludwig Schaefer, Wolfgang Wendler
  • Publication number: 20040209874
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: May 12, 2004
    Publication date: October 21, 2004
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • Publication number: 20040204406
    Abstract: The present invention is directed to a compound of formula I, 1
    Type: Application
    Filed: December 23, 2003
    Publication date: October 14, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Marc Nazare, Volkmar Wehner, David W. Will, Hans Matter
  • Publication number: 20040204407
    Abstract: The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
    Type: Application
    Filed: March 8, 2004
    Publication date: October 14, 2004
    Applicant: SUGEN Inc.
    Inventors: Peng Cho Tang, Congxin Liang, Todd Miller, Kenneth E. Lipson
  • Publication number: 20040204397
    Abstract: The present invention relates to compounds of Formula (I) 1
    Type: Application
    Filed: December 5, 2003
    Publication date: October 14, 2004
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Charles Mark Conway, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, George Tora, Shikha Vig
  • Patent number: 6803370
    Abstract: Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: October 12, 2004
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren B. Dressen, Francine S. Grant, Christopher Semko, Ying-Zi Xu
  • Publication number: 20040198720
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: February 20, 2004
    Publication date: October 7, 2004
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • Publication number: 20040186100
    Abstract: The present invention relates to a new crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1&lgr;6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide characterized by the following X-ray diffraction pattern obtained with a CuK&agr;, radiation at 2&thgr; (2Theta)=4.5, 6.4, 7.5, 7.7, 8.0, 8.2, 10.0, 10.2, 10.9, 11.1, 12.9, 13.4, 14.0, 14.5, 15.1, 15.6, 16.2, 16.5, 17.3, 17.5, 18.0, 18.9, 19.3, 19.5, 19.9, 20.1, 20.6, 21.0, 21.4, 22.7, 23.1 and 23.6 and an infrared spectrum having sharp bands at 2925, 2854, 1637, 1604, 1484, 1395, 1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 868, 860, 782, 705, 684 cm−1, and wherein the extrapolated melting point (DSC) is 137.2° C.
    Type: Application
    Filed: January 27, 2004
    Publication date: September 23, 2004
    Inventors: Torsten Hoffmann, Fabienne Hoffmann-Emery, Sonja Nick, Urs Schwitter, Pius Waldmeier
  • Publication number: 20040180881
    Abstract: Compounds which are oxazolyl-pyrazole derivatives, as defined in the specification, and pharmaceutically acceptable salts thereof; are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders.
    Type: Application
    Filed: April 15, 2004
    Publication date: September 16, 2004
    Inventors: Daniela Berta, Eduard Felder, Anna Vulpetti, Marzia Villa
  • Publication number: 20040180882
    Abstract: The present invention provides compounds having formula (I): 1
    Type: Application
    Filed: December 18, 2003
    Publication date: September 16, 2004
    Inventors: David E. Zembower, David A. Eiznhamer
  • Publication number: 20040176390
    Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-&bgr; signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: February 20, 2004
    Publication date: September 9, 2004
    Applicant: Pfizer Inc
    Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
  • Publication number: 20040176364
    Abstract: This invention relates aryl substituted thiazolidinones of Formula I: 1
    Type: Application
    Filed: March 18, 2004
    Publication date: September 9, 2004
    Applicant: Euro-Celtique S.A.
    Inventors: Qun Sun, Donald J. Kyle
  • Patent number: 6787559
    Abstract: This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: September 7, 2004
    Assignee: Syntex (U.S.A.) LLC.
    Inventors: Roland Joseph Billledeau, Chris Allen Broka, Jeffrey Allen Campbell, Jian Jeffrey Chen, Sharon Marie Dankwardt, Nancy Delaet, Leslie Ann Robinson, Keith Adrian Murray Walker
  • Publication number: 20040167116
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: February 24, 2004
    Publication date: August 26, 2004
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Mark A. Murcko, Govinda Rao Bhisetti
  • Publication number: 20040152742
    Abstract: The present invention relates to amide compounds of general formula I 1
    Type: Application
    Filed: October 31, 2003
    Publication date: August 5, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Philipp Lustenberger, Klaus Rudolf, Thorsten Lehmann-Lintz, Kirsten Arndt, Ralf Lotz, Martin Lenter, Heike-Andrea Wieland
  • Publication number: 20040127494
    Abstract: There is provided a series of novel &agr;-(N-sulfonamido)acetamide compounds of the Formula (I) 1
    Type: Application
    Filed: December 20, 2002
    Publication date: July 1, 2004
    Inventors: Michael F. Parker, Katharine E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
  • Publication number: 20040127495
    Abstract: The present invention provides a selective suppressor of the IgE production comprising a compound which suppresses the IgE production in a process from a differentiation of a mature B cell into an antibody-producing cell to the production of an antibody and which does not suppress or weakly suppresses the production of IgG, IgM and/or IgA which are produced at the same time, a compound of the formula (I): 1
    Type: Application
    Filed: November 12, 2003
    Publication date: July 1, 2004
    Applicant: Shionogi & Co., Ltd.
    Inventors: Kenji Kawada, Mitsuaki Ohtani, Ryuji Suzuki, Akinori Arimura
  • Publication number: 20040127477
    Abstract: The present invention relates to a class of compounds represented by the Formula I 1
    Type: Application
    Filed: November 20, 2003
    Publication date: July 1, 2004
    Applicant: G. D. Searle & Co.
    Inventors: Nizal Samuel Chandrakumar, Bipinchandra Nanubhai Desai, Balekudru Devadas, Alan Frank Gasiecki, Renee Huff, Ish K. Khanna, James W. Malecha, Julie M. Miyashiro, Shashidhar N. Rao, Joseph Gerace Rico, Thomas Edward Rogers, Peter Gerrard Ruminski, Mark Andrew Russell, Yi Yu
  • Publication number: 20040127488
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: July 2, 2003
    Publication date: July 1, 2004
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, John Franklin Miller, Vicente Samano
  • Publication number: 20040122004
    Abstract: The present invention relates to substituted phenylcyclohexanecarboxamides of the Formula (I) 1
    Type: Application
    Filed: November 17, 2003
    Publication date: June 24, 2004
    Applicant: Bayer Aktiengesellschaft
    Inventors: Erwin Bischoff, Thomas Krahn, Stephan-Nicholas Muller, Holger Paulsen, Joachim Schuhmacher, Henning Steinhagen, Wolfgang Thielemann
  • Publication number: 20040121995
    Abstract: Compounds of formula I: 1
    Type: Application
    Filed: October 6, 2003
    Publication date: June 24, 2004
    Inventors: Ian Churcher, Timothy Harrison, Sonia Kerrad, Alan John Nadin, Andrew Pate Owens, Duncan Edward Shaw, Joanne Thomson, Susannah Williams
  • Publication number: 20040122000
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: October 21, 2003
    Publication date: June 24, 2004
    Applicant: Vertex Pharmaceuticals Incorporated.
    Inventors: Michael R. Hale, Roger Tung, Stephen Price, Robin David Wilkes, Wayne Carl Schairer, Ashley Nicholas Jarvis, Andrew Spaltenstein, Eric Steven Furfine, Vicente Samano, Istvan Kaldor, John Franklin Miller, Michael Stephen Brieger, Ronald George Sherrill
  • Publication number: 20040116415
    Abstract: This invention relates to a method of treating disorders responsive to the blockade of sodium ion channels using novel aminoalkyl-substituted aryl compounds of Formula I: 1
    Type: Application
    Filed: July 31, 2003
    Publication date: June 17, 2004
    Applicant: Euro-Celtique S.A.
    Inventors: Qun Sun, Donald J. Kyle
  • Publication number: 20040116414
    Abstract: This invention is directed to a class of compounds (Formula I) including succinoyl amino pyrazoles, succinoyl amino thiadiazoles, succinoyl amino acid esters, succinoyl amino acid amides, succinoyl amino alcohols, succinoyl amino ketones, succinoyl amino hydantoins, succinoyl anilines, and succinoyl derivatives of privileged structures. The invention is also directed to a pharmaceutical formation comprising such compound in a pharmaceutically acceptable salt form or prodrug thereof. The invention is further directed to a method for inhibiting &bgr;-amyloid peptide release and/or synthesis, a method for inhibiting &ggr;-secretase activity and a method for treating neurological disorders associated with &bgr;-amyloid peptide production. The method comprises administering to a host a pharmaceutical formulation comprising an effective amount of a compound of Formula I. The compounds of Formula I are useful in the prevention and treatment of Alzheimer's disease.
    Type: Application
    Filed: May 7, 2003
    Publication date: June 17, 2004
    Inventors: Jay S. Tung, Ashley C. Guinn, Eugene D. Thorsett, Michael A. Pleiss
  • Publication number: 20040116404
    Abstract: Disclosed are sulphones which modulate the action of gamma-secretase. The compounds are useful in the treatment or prevention of Alzheimer's disease.
    Type: Application
    Filed: October 1, 2003
    Publication date: June 17, 2004
    Inventors: Jose Luis Castro Pineiro, Ian Churcher, Kevin Dinnell, Timothy Harrison, Sonia Kerrad, Alan John Nadin, Paul Joseph Oakley, Andrew Pate Owens, Duncan Edward Shaw, Martin Richard Teall, Susannah William, Brian John Williams
  • Publication number: 20040110748
    Abstract: The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: September 18, 2003
    Publication date: June 10, 2004
    Inventors: Lisa Selsam Beavers, Robert Alan Gadski, Philip Arthur Hipskind, Craig William Lindsley, Karen Lynn Lobb, James Arthur Nixon, Richard Todd Pickard, John Mehnert Schaus, Takako Takakuwa, Brian Morgan Watson
  • Publication number: 20040110736
    Abstract: The present application describes modulators of MCP-1 of formula (I): 1
    Type: Application
    Filed: November 12, 2003
    Publication date: June 10, 2004
    Inventor: Robert Cherney
  • Publication number: 20040102437
    Abstract: Compounds having an Rho kinase inhibitory activity. These compounds include the compound of general formula (I): Het-X-Z, pharmaceutically acceptable salts thereof and solvates of the same, wherein Het represents a monocyclic or dicyclic heterocycle group containing at least one nitrogen atom (for example, pyridyl, phthalimido); X represents (i) an —NH—C(═O)—NH-Q1- group, (ii) an —NH—C(═O)-Q2- group, etc. (wherein Q1 and Q2 represent each a bond, alkylene or alkenylene); and Z represents hydrogen, halogeno, a monocyclic, dicyclic ortricyclic carbon cycle or heterocycle, etc. (for example, optionally substituted phenyl).
    Type: Application
    Filed: May 19, 2003
    Publication date: May 27, 2004
    Inventors: Atsuya Takami, Hiroshi Iijima, Masayuki Iwakubo, Yuji Okada
  • Publication number: 20040097496
    Abstract: A compound having 3-oxo-3,4-dihydro-2H-1,4-thiazine 4-tetrahydropyrazine as a main skeleton.
    Type: Application
    Filed: November 13, 2003
    Publication date: May 20, 2004
    Applicant: SANTEN PHARMACEUTICAL CO.,LTD.
    Inventors: Kazuo Nishimura, Masakazu Ban, Ken-Ichi Fujimura, Naoyuki Kobayashi, Masanori Hori, Takahiro Honda, Junzo Matsumoto, Eiko Matsumoto